US FDA grants final approval to Strides' injectible acetazolamide

10 May 2012

1

Bangalore-based Strides Arcolab today said that it has received ANDA approval from US FDA for its acetazolamide for injection USP in dosages of  500 mg/ vial (preservative free) in lyophilised format.

Acetazolamide, is used for adjunctive treatment of edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

According to IMS, the 2011 U.S. market for Injectable Acetazolamide approximates to $10 million with only one active player. The product is expected to be launched shortly.

Acetazolamide is the 14th product approved under the Sagent - Strides partnership, under which strides is developing and supplying more than 25 injectable products for the US market which will be marketed by privately-held specialty pharmaceutical firm Sagent

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more